Skip to main content

Meeting Materials

Poster

93
Introduction: Cognitive impairments associated with schizophrenia are burdensome and detrimental to everyday life. The Schizophrenia Cognition Rating Scale (SCoRS) is a 20-item interview-...
08/20/2024
25
Introduction: Currently, no FDA-approved pharmacological treatments satisfactorily address experiential negative symptoms (ENS) of schizophrenia. CT-155/BI 3972080 (CT-155 beta), is a pre...
08/20/2024
40
INTRODUCTION: Long-term safety, tolerability, and durability of therapeutic effect are important aspects of antipsychotic treatment.
08/20/2024
199
LY03010 (paliperidone palmitate) is in development as a pharmaceutical equivalent drug product to the listed drug (LD), INVEGA SUSTENNA® for schizophrenia and schizoaffective disorders wi...
08/20/2024
184
Introduction: Iclepertin (BI 425809), a glycine transporter-1 inhibitor, has improved cognitive impairment associated with schizophrenia (CIAS) in Phase II trials, with Phase III trials u...
08/20/2024
177
Purpose: Agitation treatment in patients with schizophrenia or bipolar disorder is challenging. Alpha-2 agonist, IGALMI™ DSF (dexmedetomidine sublingual film) reduces norepinephrine. Real...
08/20/2024
198
Introduction: Major Depressive Disorder (MDD) is characterized by depressed mood and diminished quality of life. Patient characteristics as well as patients’ experience of and response to...
08/20/2024
161
Background: This analysis used population pharmacokinetic (PopPK) modeling to characterize dosing conversions and switching strategies from intramuscular paliperidone palmitate once month...
08/20/2024
100
INTRODUCTION: Initiation of the long-acting injectable antipsychotic aripiprazole lauroxil (AL) using a one-time injection of a NanoCrystal Dispersion formulation of AL (ALNCD) and a 30 m...
08/20/2024
4
Objective: To evaluate lipid and anti-diabetic medication use pre-/post-cariprazine initiation in patients with bipolar I disorder (BP-I) or major depressive disorder (MDD).
11/26/2024
5
Introduction: Peripartum or postpartum depression (PPD) is a major depressive episode (MDE) with peripartum onset. Specific international classification of diseases (ICD) codes for PPD ar...
11/26/2024
6
Introduction: Peripartum or postpartum depression (PPD) is a major depressive episode with peripartum onset. Despite its prevalence, PPD is under-screened, underdiagnosed, and undertreate...
11/26/2024
7
Introduction A similar final common pathophysiological pathway exists between clozapine hypersensitivity, COVID infection, and certain COVID vaccines (mRNA) against heart muscle. Minimizi...
11/26/2024
8
Background: Epidemiological estimates of schizophrenia vary considerably. The aim of this study was to assess current national incidence and prevalence rates of schizophrenia in the U.S. ...
11/26/2024
9
Background: Negative symptoms in schizophrenia (NSS) and cognitive impairment associated with schizophrenia (CIAS) are linked to poor prognosis. Real-world data (RWD) from electronic heal...
11/26/2024
10
Current schizophrenia treatments often cause metabolic disturbances. KarXT, an investigational medication combining xanomeline, a muscarinic receptor agonist, and trospium chloride, a mus...
11/26/2024
11
Introduction: In the phase 3 REST-ON trial (NCT02720744), once-nightly sodium oxybate (ON-SXB) treatment in participants with narcolepsy type 1 (NT1) and 2 (NT2) resulted in statistically...
11/26/2024
12
Introduction: Research was undertaken to better understand the path to a narcolepsy diagnosis, common symptoms, and impact on work, social interactions, and mental health for people with ...
11/26/2024
13
Introduction: Immediate-release (IR) oxybate formulations require patients to awaken 2.5 to 4 hours after their first dose for a second dose. Once-nightly sodium oxybate (ON-SXB) is an ex...
11/26/2024
14
Introduction: People with narcolepsy (PWN) were surveyed to better understand desired treatment outcomes and how they relate to common symptoms, treatment awareness, and medication usage....
11/26/2024
15
Introduction: To further characterize struggles and unmet needs of people with narcolepsy (PWN), passive social listening (SL) explored how PWN describe narcolepsy using their own words. ...
11/26/2024
16
Introduction: In patients with major depressive disorder (MDD), the effects of prominent anhedonia on psychotropic medication use, healthcare resource utilization (HCRU), and health-relat...
11/26/2024
17
Hypothesis/Objective: To evaluate the effect of centanafadine (CTN), a norepinephrine, dopamine, serotonin reuptake inhibitor, on ADHD symptoms and severity from two studies in pediatric ...
11/26/2024
18
Hypothesis/Objective: Evaluate caregiver and patient perspectives of the impact of centanafadine (CTN), a norepinephrine, dopamine, serotonin reuptake inhibitor, on learning problems (LP)...
11/26/2024
19
The number of long-acting injectable (LAI) antipsychotic formulations approved for the treatment of schizophrenia (SCZ) or bipolar I disorder (BP-I) is increasing, with new dosing interva...
11/26/2024
20
Introduction: Psychiatric comorbidities are common in patients with excessive daytime sleepiness (EDS) from narcolepsy or obstructive sleep apnea (OSA). Solriamfetol (Sunosi®), a dopamine...
11/26/2024
21
Introduction: An artificial intelligence–based semantic analysis of social media posts was carried out to reveal the burden of cognitive symptoms on the daily lives of people with schizop...
11/26/2024
22
Introduction: Although the clinician perspective of schizophrenia is commonly reported and patients complete questionnaires about their disease, the spontaneous, subjective experience of ...
11/26/2024
23
Introduction: ALKS 2680 is a potent, centrally active, orally bioavailable, and highly selective orexin 2 receptor agonist being developed for the once-daily treatment of narcolepsy. Here...
11/26/2024
24
Post-traumatic stress disorder (PTSD) among civilians is a significant contributor to healthcare costs and functional impairment in the United States. While approved evidence-based treatm...
11/26/2024
26
Introduction: Post-traumatic stress disorder (PTSD) is a psychiatric disorder characterized by a variety of symptoms impairing one’s functioning. Manifestations of PTSD are complex, posin...
11/26/2024
27
Introduction: Tardive dyskinesia (TD) is a movement disorder associated with prolonged exposure to dopamine receptor blocking agents that can significantly impact one’s quality of life (Q...
11/26/2024
28
Introduction: Tardive dyskinesia (TD) is a potentially disabling involuntary movement disorder due to dopamine receptor-blocking agent exposure and can impair physical, psychological, fun...
11/26/2024
29
Background: Tardive dyskinesia (TD) significantly impacts quality of life (QoL) beyond movement symptoms. A web-based survey and chart extraction among US physicians, nurse practitioners,...
11/26/2024
30
Objective: Esketamine (Spravato®) nasal spray, an NMDA receptor antagonist, is FDA-approved for use with an oral antidepressant in adults with treatment-resistant depression. Each outpati...
11/26/2024
31
Objective: We describe 2 Phase II, multicenter, randomized, double-blind, placebo-controlled trials to provide proof of concept and dose selection for BI 1569912 for the treatment of majo...
11/26/2024
32
Anhedonia is a core feature of major depressive disorder (MDD) yet its clinical burden on patients is not well understood. This retrospective cohort study assessed depression symptoms and...
11/26/2024
33
Brexpiprazole is an atypical antipsychotic approved for use as an adjunctive therapy for treatment of Major Depressive Disorder (MDD). This retrospective cohort study assessed depressive ...
11/26/2024
34
Objective: Little real-world evidence exists comparing the benefits of long-acting injectables (LAIs) relative to daily oral antipsychotics (OAPs) in the Medicare population, which includ...
11/26/2024
35
Introduction: This study described the clinical and humanistic burden of idiopathic hypersomnia.
11/26/2024
37
Although SSRIs are the first-line treatment for major depressive disorder, providers may be hesitant to initiate a trial of SSRI if the patient presented with drug induced liver injury as...
11/26/2024
38
Aim: To assess treatment patterns in patients with attention-deficit hyperactivity disorder (ADHD) treated with serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) or comparators using r...
11/26/2024
39
BACKGROUND: The United States (US) Food and Drug Administration (FDA) approved once-every-6-months paliperidone palmitate (PP6M) on 09/01/2021. However, limited real-world evidence exists...
11/26/2024
41
Introduction: Pharmacological treatments for negative and cognitive symptoms in schizophrenia spectrum disorders (SSD) are lacking, and evidence-based psychosocial interventions are inacc...
11/26/2024
42
Background: Relapse in schizophrenia adversely affects patient outcomes, yet its influence on mortality is not well characterized.
11/26/2024
43
Background: Azetukalner is a novel, potent KV7 potassium channel opener in clinical development for epilepsy and major depressive disorder (MDD).
11/26/2024
44
Cohen’s d effect sizes, which describe standardized differences between two means (e.g., mean score changes for placebo and active drug in a clinical trial), are used to compare effects a...
11/26/2024
45
Background: Alzheimer’s disease agitation (ADA) is characterized by emotional distress, aggression, and disinhibition. AXS-05 (dextromethorphan-bupropion) is a novel, oral NMDA receptor a...
11/26/2024
46
Introduction: Research exploring patients’ experiences with idiopathic hypersomnia is limited. This qualitative study explored patients’ perspectives on the most relevant and important sy...
11/26/2024
47
Introduction: Sleep inertia, a core symptom and distinguishing feature of idiopathic hypersomnia, refers to difficulty awakening. This qualitative study generated insights into the experi...
11/26/2024
48
Tardive dyskinesia (TD) can profoundly impact patients’ daily functioning and overall quality of life, making appropriate diagnosis and management critical. This study aimed to identify c...
11/26/2024
49
Introduction: Narcolepsy type 1 (NT1) is a neurologic disorder characterized by excessive daytime sleepiness and cataplexy. Cognitive impairment, a disruptive symptom of NT1, is character...
11/26/2024
50
Objectives: Real world evidence has shown the benefits of initiating aripiprazole once-monthly 400 mg (AOM 400) early in patients living with schizophrenia; however, the impact on patient...
11/26/2024
51
Patients with major depressive disorder (MDD) can be prescribed atypical antipsychotics (AAPs) as adjunctive therapies but there is a lack of real-world evidence to understand prescribing...
11/26/2024
52
Hypothesis/Objective: To evaluate the impact of centanafadine (CTN), a norepinephrine, dopamine, serotonin reuptake inhibitor, on inattention and hyperactivity/impulsivity via caregiver-r...
11/26/2024
54
Introduction: Visuospatial attention deficits are a key characteristic of ADHD. BrianGaze is an innovative technology that leverages eye-tracking to capture changes in the angle of eye ve...
11/26/2024
55
Introduction: Several atypical antipsychotics (AAs) are approved as adjunctive treatment for major depressive disorder (MDD). Given high disability burden among MDD patients, evaluation o...
11/26/2024
56
Introduction: Non-selective N-methyl-D-aspartate (NMDA) receptor antagonists (e.g. ketamine/esketamine) have demonstrated efficacy in the treatment of MDD; however, these agents are assoc...
11/26/2024
57
Introduction: SPN-820 (oral formulation of NV-5138), is a first-in-class, rapid-acting antidepressant (RAAD) drug candidate that acts intracellularly to increase mechanistic target of ra...
11/26/2024
58
Objective: To better understand Native American patients’ experiences and perceptions of depression and treatment. Methods: Educational sessions hosted by three Tribal Health Centers brou...
11/26/2024
59
Background: Seltorexant, a selective human orexin-2 receptor antagonist, is being developed for adjunctive treatment of major depressive disorder with insomnia symptoms. This phase 1 stud...
11/26/2024
60
Objective: To compare healthcare resource utilization (HCRU) and cost among Medicaid patients with serious mental illness (SMI) based on state reimbursement rates.
11/26/2024
61
Objective: To compare psychiatry-related and all-cause healthcare resource utilization (HCRU), costs, incarceration rates, and homelessness rates among states with and without an IMD excl...
11/26/2024
62
INTRODUCTION: The combination of olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM treatme...
11/26/2024
63
INTRODUCTION: The combination of olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM treatme...
11/26/2024
64
Anhedonia is a key symptom of Major Depressive Disorder (MDD), however, there is limited knowledge about the impact of prominent anhedonia on clinical improvement and treatment satisfacti...
11/26/2024
65
KarXT, an investigational treatment for schizophrenia, combines the M1/M4 preferring muscarinic receptor agonist xanomeline with the peripherally restricted muscarinic receptor antagonist...
11/26/2024
66
Background: In data pooled from the EMERGENT-1 (NCT03697252), EMERGENT-2 (NCT04659161), and EMERGENT-3 (NCT04738123) clinical trials of adults with schizophrenia, xanomeline and trospium ...
11/26/2024
67
Introduction: The dual M1/M4 preferring muscarinic receptor agonist xanomeline in combination with the peripherally restricted pan muscarinic receptor antagonist trospium chloride is an i...
11/26/2024
68
Positive symptoms of schizophrenia (ie, psychosis) are driven by dopaminergic hyperactivity. Currently approved antipsychotics block postsynaptic D2 dopamine receptors but do not target t...
11/26/2024
69
INTRODUCTION: This post-hoc analysis examined the efficacy and safety of aripiprazole lauroxil (AL) by baseline severity of illness in the double-blind ALPINE study (NCT03345979) in patie...
11/26/2024
70
INTRODUCTION: Long-acting injectable (LAI) antipsychotic medications ensure that patients have consistent medication exposure across dosing intervals that can last 1 month or more, potent...
11/26/2024
71
Objective: Review safety and efficacy outcomes for participants with concomitant stimulant use in an open-label extension (OLE) after completing a phase 3, placebo-controlled, double-blin...
11/26/2024
72
Objective: Evaluate body weight (BW) changes with viloxazine extended release (VLX-ER) in a phase 3, double-blind, 6-week trial [NCT04016779] for adult ADHD, and its ensuing long-term, op...
11/26/2024
73
OBJECTIVE: Historically, girls and women have been thought to have milder cases of ADHD and present with predominantly inattentive ADHD symptoms. This post-hoc analysis of viloxazine ER c...
11/26/2024
74
Background: Despite increasing ADHD treatment in women, ADHD medication safety in pregnancy and lactation is not well documented. Viloxazine ER is the first ADHD medication studied under ...
11/26/2024
75
Background: A dose-response evaluation of single-dose MM120 (lysergide D-tartrate) investigated functional disability (FD), sexual dysfunction (SD), and quality of life (QoL) secondary ou...
11/26/2024
76
The patient is a 44-year-old male, diagnosed with bipolar disorder, type II and generalized anxiety disorder. He has a long history of mood swings, depression, and anxiety. Since age 18, ...
11/26/2024
77
Introduction: Based on the results of the pivotal MIRAI trial (NCT04770285), CT-152 received FDA clearance as a prescription digital therapeutic adjunct to antidepressant treatment (ADT) ...
11/26/2024
78
Introduction: CT-152 is an FDA cleared prescription digital therapeutic for treating patients with major depressive disorder (MDD) as an adjunct to antidepressant medication. The durabili...
11/26/2024
79
Introduction: CT-152 received FDA 510(k)-clearance as a prescription digital therapeutic adjunct to antidepressant treatment (ADT) in patients with major depressive disorder (MDD). CT-152...
11/26/2024
80
Objective The need for additional ADHD medication options as monotherapy or in combination with stimulants exists, as not all patients respond optimally to stimulants, which are often use...
11/26/2024
81
Background: This study assessing patient’s real-world experience through PatientsLikeMe (PLM) online platform, aims to understand the treatment experience of patients with major depressiv...
11/26/2024
82
Introduction: High sodium intake can increase blood pressure (BP) and cardiovascular risk. Individuals with narcolepsy have elevated cardiovascular comorbidity burden before considering m...
11/26/2024
83
Introduction: Psychiatric comorbidities (PC) are common in patients with idiopathic hypersomnia (IH). Low-sodium oxybate (LXB; Xywav®) is approved by the US FDA for the treatment of IH in...
11/26/2024
84
OBJECTIVE: Viloxazine extended-release (VLX-ER) is a nonstimulant FDA-approved medication for pediatric and adult ADHD treatment. Patients with ADHD often have psychiatric comorbidities, ...
11/26/2024
85
Introduction: Lumateperone is an FDA-approved antipsychotic for schizophrenia and bipolar depression. This Phase 3, randomized, double-blind, placebo-controlled, multicenter trial (NCT050...
11/26/2024
86
OBJECTIVE: To assess in Alzheimer’s disease (AD), the treatment impact of donanemab, an amyloid plaque-reducing monoclonal antibody, on readily interpretable item-measures and constructs ...
11/26/2024
87
Objective: To characterize the efficacy and safety associated with donanemab, a novel amyloid-targeting therapy (ATT).
11/26/2024
88
Bipolar I disorder (BP-I) is characterized by extremes of the mood spectrum. People diagnosed with BP-I often have comorbid mental health conditions, necessitating the use of additional p...
11/26/2024
90
The US is currently experiencing a mental health crisis, with nearly 25% of adults suffering from a mental health disorder and 29% unsure of where to seek services. This significant deman...
11/26/2024
91
According to the Health Resources and Services Administration (HRSA), more than half of the U.S. population resides in a Mental Health Professional Shortage Area (MHPSA). To address this ...
11/26/2024
92
Introduction: This analysis evaluated the effect of solriamfetol (Sunosi®), approved to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA; 37.5–150 mg/...
11/26/2024
94
The current study examines the relationship between bicultural identity integration (BII) and bicultural students’ academic performance and mental health. A sample of 86 bicultural studen...
11/26/2024
96
TV-44749 is once-monthly, subcutaneous, extended-release injectable based on innovative copolymer delivery technology that ensures controlled release of olanzapine, designed to provide su...
11/26/2024
97
Use of intramuscular long-acting injectable (LAI) olanzapine is limited due to a boxed warning for post-injection delirium/sedation syndrome (PDSS) and associated REMS. PDSS may arise fro...
11/26/2024
98
Background: Valbenazine is a once-daily medication approved for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington’s disease. Data from a 48-week, open-label s...
11/26/2024
99
Introduction: This semantic analysis of social media posts captured unsolicited, real-world experiences from people with schizophrenia to examine the impact of cognitive impairment on qua...
11/26/2024
101
Background: Postpartum depression (PPD) can impair functioning and quality of life (QoL). The Junonia study evaluated characteristics and QoL of patients with moderate or severe PPD sympt...
11/26/2024
102
Objective: To describe weight and metabolic changes associated with esketamine nasal spray (ESK) versus quetiapine extended release (QXR) treatment in patients with treatment-resistant de...
11/26/2024
103
Background: Paliperidone palmitate (PP), available as 1-month (PP1M), 3-month (PP3M) and 6-month (PP6M) formulations, has demonstrated efficacy in reducing the risk of relapse and delayin...
11/26/2024
104
Additional pharmacotherapies are needed for post-traumatic stress disorder (PTSD). This pooled post-hoc analysis evaluated key clinical efficacy data for brexpiprazole in combination with...
11/26/2024
105
A well-tolerated pharmacotherapy with consistent efficacy is needed for PTSD. This report summarizes safety data from three PTSD trials of brexpiprazole + sertraline.
11/26/2024
106
Post-traumatic stress disorder (PTSD) is a highly prevalent disorder with heterogeneous and burdensome symptoms across four symptom clusters: intrusion/re-experiencing, avoidance, negativ...
11/26/2024
107
Background: People with major depressive disorder (MDD) have an increased risk of obesity, and weight gain has been linked to antipsychotics and antidepressants (ADTs). This underscores t...
11/26/2024
108
Background: To characterize safety outcomes of adjunctive cariprazine by background antidepressant therapy (ADT), post hoc analyses were conducted on data from 2 randomized controlled tri...
11/26/2024
109
Background: Post hoc analyses of phase 3 trials for adjunctive cariprazine in major depressive disorder (MDD) characterized 4 common treatment-emergent adverse events (TEAEs).
11/26/2024
110
Background: HP-3070 (asenapine transdermal system) is indicated for adults with schizophrenia. The Food and Drug Administration recommends analyzing clinical outcome data to determine wha...
11/26/2024
111
Background: d-ATS is a transdermal dextroamphetamine formulation approved for treating ADHD in patients ≥6 years old. This study evaluates the effect of external heat on rate and extent o...
11/26/2024
112
Objective: Esketamine (ESK) nasal spray is approved in 75 countries for treatment-resistant depression (TRD) in conjunction with an oral antidepressant (OAD). Efficacy and safety of ESK m...
11/26/2024
113
Objective: Anhedonia is a key symptom and part of the diagnostic criterion of major depressive disorder (MDD). However, the relationship between anhedonia and the clinical and humanistic ...
11/26/2024
114
Background: Once-daily valbenazine is approved for tardive dyskinesia (TD) and Huntington’s disease (HD) chorea. Dysphagia is common in both disorders, and alternative modes for oral medi...
11/26/2024
115
Background Agitation associated with Dementia due to Alzheimer’s disease (AADAD), characterized by exaggerated motor activity and verbal and/or physical aggression, is common in Alzheimer...
11/26/2024
116
Introduction: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and bipolar depression. A recent randomized, double-blind, placebo-controlled trial (NCT04285515) demons...
11/26/2024
117
Introduction: Patient interviews were completed to obtain in-depth insights into excessive daytime sleepiness (EDS) experienced in idiopathic hypersomnia, obstructive sleep apnea (OSA), a...
11/26/2024
118
INTRODUCTION: Efficacy and safety of the combination of olanzapine and samidorphan (OLZ/SAM) were assessed in 6 phase 3 studies of adults with schizophrenia or bipolar I disorder. We revi...
11/26/2024
119
INTRODUCTION: Addressing negative symptoms of schizophrenia can be a treatment challenge. This post hoc analysis examined the long-term effect of the combination of olanzapine and samidor...
11/26/2024
120
Short-term safety and efficacy outcomes of centanafadine versus common attention-deficit/hyperactivity disorder (ADHD) treatments were evaluated in pediatric patients using matching-adjus...
11/26/2024
121
Objectives: To expand prior network meta-analyses investigating the relative efficacy, safety, and tolerability of xanomeline and trospium (KarXT), for the acute treatment of schizophreni...
11/26/2024
122
There is great interest in psychedelic treatments for a range of psychiatric conditions. Although many neuropsychiatric treatments have psychoactive effects, the acute effects of psychede...
11/26/2024
123
Delusions of pregnancy are fixed beliefs that one is pregnant despite evidence to the contrary. Several psychosocial factors are implicated in such delusions. This case report discusses s...
11/26/2024
124
Background: This double-blind, randomized, placebo-controlled phase 3 study (NCT04533529) compared the efficacy and safety of adjunctive seltorexant to placebo in participants with major ...
11/26/2024
125
Introduction: Narcolepsy, a rare, chronic neurological condition characterized by excessive daytime sleepiness, is associated with negative impacts to patients’ lives. Studies examining t...
11/26/2024
126
Introduction: Narcolepsy is a rare, chronic neurological disorder characterized by excessive daytime sleepiness among other symptoms, that can negatively impact patients’ lives. This stud...
11/26/2024
127
Background: The Pathway Platform was designed to enhance patient-provider engagement and encourage use of outcome measures for major depressive disorder (MDD) to improve adherence to meas...
11/26/2024
128
Background: PPD is a potentially severe mood disorder that affects 1 in 7 women within the first year after childbirth. BRII-296 is an extended-release intramuscular (IM) injectable brexa...
11/26/2024
129
Patients presenting to the Behavioral Health Emergency Room and requiring admission may have co-occurring pain, which can significantly impact their mental health. Pain management is chal...
11/26/2024
130
Background There is limited understanding of how tardive dyskinesia (TD) affects individuals with different underlying psychiatric conditions.
11/26/2024
131
Background: CT-152 received FDA clearance as a prescription digital therapeutic adjunct to antidepressant (ADT) medications for symptoms of major depressive disorder (MDD). A network meta...
11/26/2024
132
Background: The FDA recently authorized CT-152 as a prescription digital therapeutic adjunct to antidepressant (ADT) medications for patients with major depressive disorder (MDD).
11/26/2024
133
Background: Cognitive impairment is an underacknowledged aspect of schizophrenia. Individuals with schizophrenia struggle with memory, attention, and executive functioning causing conside...
11/26/2024
134
Introduction: Cognitive impairments (CI) significantly burden over half of patients with schizophrenia in the United States. Given the extensive research on treating CI, we provide a revi...
11/26/2024
135
Background: Schizophrenia is a complex condition characterized by both positive and negative symptoms. Often underrecognized are the cognitive impairments (CI). The objective of this stud...
11/26/2024
136
Neuroscience is driving a transformative shift in psychiatry, with brain neuroimaging at the forefront of personalized medicine. This poster presents preclinical and clinical approaches t...
11/26/2024
137
Introduction: Patient-digital therapeutic (DTx) bonds (digital working alliance [DWA]) may be important for DTx success. Aims: To assess whether a DWA could be established between partici...
11/26/2024
138
Background: Tardive dyskinesia (TD) is a hyperkinetic movement disorder resulting from chronic exposure to antipsychotics. TD is underdiagnosed; understanding barriers to diagnosis is an ...
11/26/2024
139
Objectives: Pimavanserin (PIM) is the only FDA approved atypical antipsychotic (AAP) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP);...
11/26/2024
140
All US antipsychotic labels include boxed warnings of mortality risk in older patients with dementia-related psychosis. We compared mortality risk in patients with Parkinson’s disease psy...
11/26/2024
141
Pimavanserin is the only FDA-approved medication indicated for treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). Earlier treatment of mild PDP...
11/26/2024
142
Lewy Body Dementia is an umbrella term (including dementia with Lewy Bodies [DLB] and Parkinson’s disease dementia [PDD]), for dementias associated with Lewy bodies or abnormal brain depo...
11/26/2024
143
Introduction: Navacaprant is a highly selective kappa opioid receptor antagonist with promising efficacy and safety findings in a Phase 2 major depressive disorder (MDD) study. This post-...
11/26/2024
144
Introduction: This Phase 2 study assessed efficacy and safety of navacaprant, a highly selective kappa opioid receptor antagonist, in adults with major depressive disorder (MDD).
11/26/2024
145
Major depressive disorder (MDD) is often compounded by clinically relevant insomnia symptoms (MDD-CRIS; warranting clinical attention), causing anxiety, sleep deprivation, and impaired pr...
11/26/2024
146
Major depressive disorder (MDD) patients often experience insomnia symptoms as part of their depression. This survey aimed to evaluate MDD patient needs for adjunctive treatment for insom...
11/26/2024
147
Anhedonia is a core symptom of major depressive disorder (MDD). However, there is a lack of understanding of the healthcare and humanistic burden associated with prominent anhedonia in pa...
11/26/2024
149
Hypothesis/Objective: Evaluate the efficacy and safety of once-daily extended-release centanafadine (CTN), a norepinephrine, dopamine, serotonin reuptake inhibitor, for ADHD treatment in ...
11/26/2024
150
Background: Pseudoseizures, or psychogenic non-epileptic seizures (PNES), mimic epileptic seizures but are psychological in origin, lacking abnormal electrical activity on an electroencep...
11/26/2024
151
Purpose: To examine real-world incidence of adverse events of special interest (AESIs), specifically, actively solicited events of sedation, dissociation, and increased blood pressure (BP...
11/26/2024
152
Acute agitation is common in people with schizophrenia, and the Positive and Negative Syndrome Scale – Excited Component (PANSS–EC composed of excitement, tension, hostility, uncooperativ...
11/26/2024
153
Introduction: Iclepertin (BI 425809) is a GlyT1 inhibitor in Phase III development for CIAS. Aims: To assess the safety of iclepertin in Phase I (N&#3f391 healthy volunteers [HV]; 339...
11/26/2024
154
Background: Major Depressive Disorder (MDD) is a prevalent psychiatric disorder, affecting an estimated one in five U.S. adults during their lifetime. This study aims to assess the clinic...
11/26/2024
155
Background: Negative symptoms (NS) in schizophrenia (blunted affect, alogia, avolition, asociality, and anhedonia) significantly contribute to long-term disability and diminished function...
11/26/2024
156
Background: Deutetrabenazine is approved by the United States Food and Drug Administration for treatment of tardive dyskinesia (TD) and chorea in Huntington disease (HD). This interim ana...
11/26/2024
157
Background: Real-world data on antidepressant (AD) treatment for major depressive disorder (MDD) in clinical practice are limited for all ADs including vortioxetine.
11/26/2024
158
Purpose: To investigate real-world outcomes pre- and post- pharmacogenomic (PGx) testing, this study determined 1) the proportion of patients with major depressive disorder (MDD) taking m...
11/26/2024
159
Although the relationship between stress and self-control has been studied, it is unclear if the relationship follows a linear versus an inverted U-shaped model, the latter suggesting sel...
11/26/2024
160
Background Postpartum depression (PPD) is a serious, under-studied pregnancy-related complication. Racial disparities and financial barriers can impede access to PPD treatment. Methods An...
11/26/2024
162
Background: Cognitive impairment associated with schizophrenia (CIAS) is observed in approximately 80% of schizophrenia patients and viewed as having the strongest influence on everyday f...
11/26/2024
163
Noonan syndrome (NS) is a genetic disorder with cardinal features such as unusual facies, short stature, congenital heart defects and intellectual disability or developmental delay. It is...
11/26/2024
164
Introduction: Patients with narcolepsy often exhibit neuropsychological deficits, particularly in alertness, attention, executive function, and decision-making. Solriamfetol (Sunosi®), a ...
11/26/2024
165
Introduction: Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, open-label study (NCT05875974) e...
11/26/2024
166
Introduction: Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, open-label study (NCT05875974) e...
11/26/2024
167
Background: This study evaluated if central raters (CRs) in psychedelic clinical research trials experience functional unblinding to treatment allocation while assessing key endpoints due...
11/26/2024
168
Introduction: Narcolepsy type 1 (NT1) involves excessive daytime sleepiness and cataplexy episodes and is defined by low orexin levels. TAK-861, an orexin receptor 2 agonist, showed wake-...
11/26/2024
169
Introduction: Narcolepsy type 1 (NT1) involves excessive daytime sleepiness and cataplexy associated with low CSF orexin levels. TAK-861, an orexin receptor 2 agonist, showed wake-promoti...
11/26/2024
170
Introduction: ALKS 2680 is a potent, centrally active, orally bioavailable, and highly selective orexin 2 receptor agonist being developed for the once-daily treatment of narcolepsy. Safe...
11/26/2024
171
Background: Many patients with major depressive disorder (MDD) experience enduring tolerability problems associated with antidepressant treatments (ADTs), leading to discontinuation and d...
11/26/2024
172
Background: Traditional antidepressant monotherapies are associated with poor outcomes in patients with impaired symptom domains of anhedonia and interest-activity. AXS-05 (dextromethorph...
11/26/2024
173
Several treatment modalities are available for patients with PTSD, including pharmacotherapy, psychotherapy, and combination therapy. This research aims to evaluate the factors associated...
11/26/2024
174
Patient experience, including physical, mental, and emotional Quality of Life (QoL) are not well understood in post-traumatic stress disorder (PTSD) management. This study aims to underst...
11/26/2024
175
Background: While the psychological impact of posttraumatic stress disorder (PTSD) is well known, its consequences on physical health and social functioning are not well documented. We sy...
11/26/2024
176
The factors that drive willingness to seek care among civilian trauma survivors with PTSD are not well understood. Understanding these drivers is important to identify opportunities to op...
11/26/2024
178
Background: Deutetrabenazine (DTBZ) is used for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington disease. DTBZ dosing starts at 12 mg/d and is titrated up by...
11/26/2024
179
Background: Deutetrabenazine demonstrated clinically significant improvements in Abnormal Involuntary Movement Scale (AIMS) scores in 12-week pivotal tardive dyskinesia (TD) trials (ARM-T...
11/26/2024
180
Individuals most in need of mental health care are often the ones who lack equitable access. Medically-underserved populations (MUPs) consist of marginalized groups who do not have adequa...
11/26/2024
181
Background TV-46000, a long-acting injectable risperidone formulation administered subcutaneously once monthly (q1m) or once every 2 months (q2m), is approved for the treatment of schizop...
11/26/2024
182
Background: TV-46000, a subcutaneous long-acting injectable risperidone formulation administered once monthly (q1m) or once every 2 months (q2m), was approved in the US in April 2023 for ...
11/26/2024
185
Introduction: Digital therapeutics (DTx) are a new treatment class for major depressive disorder (MDD). CT-152 is a novel prescription DTx recently cleared by the FDA. This randomized con...
11/26/2024
186
Background Anhedonia, a core symptom of major depressive disorder (MDD), impacts patients' quality of life and treatment outcomes. However, limited data exist on how anhedonia is dis...
11/26/2024
187
Introduction: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and bipolar depression. This Phase 3, randomized, double-blind, placebo-controlled, multicenter, interna...
11/26/2024
188
Background: This study evaluated the dose-response relationship of efficacy, safety, and tolerability for single-dose MM120 (lysergide D-tartrate) vs placebo in participants with generali...
11/26/2024
189
Risperidone, an atypical antipsychotic, is known to be the most likely of its class of medication to cause hyperprolactinemia. We present a case of a 33 year old female with no known psyc...
11/26/2024
190
Purpose: To examine whether a continuing medical education (CME) curriculum intervention can improve provider knowledge, competence, and confidence in individualizing treatment plans for ...
11/26/2024
191
Physicians are challenged to fully understand the pathophysiology of major depressive disorder (MDD) and identify the role of novel therapies. Individualizing treatment for patients with...
11/26/2024
192
This study examined whether an online CME clinical demonstration module can improve learners’ self-reported clinical behaviors related to management of MDD, identifying patients who may b...
11/26/2024
193
Background: Digital therapeutic technologies (DTx) are emerging rapidly, and clinicians are challenged to understand their benefits and how they fit into practice. Physicians require educ...
11/26/2024
194
KarXT is a novel investigational muscarinic M1/M4 receptor agonist that, unlike currently available antipsychotics, does not directly block dopamine D2 receptors. A new drug application f...
11/26/2024
195
KarXT is a novel treatment that does not directly block dopamine D2 receptors. A new drug application for KarXT was recently accepted by the FDA to treat schizophrenia in adults. As KarXT...
11/26/2024
196
KarXT is a novel treatment that does not directly block dopamine D2 receptors. A new drug application for KarXT was recently accepted by the FDA to treat schizophrenia in adults. An impor...
11/26/2024
197
Introduction: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or II disorder. This prospectively defined analysis of...
11/26/2024
200
BACKGROUND: Esketamine nasal spray and transcranial magnetic stimulation (TMS) are used for treatment-resistant depression (TRD), but little is known about the sequence in which these the...
11/26/2024
201
BACKGROUND: Clinical trials for esketamine nasal spray in treatment resistant depression (TRD) often assess efficacy using Montgomery-Asberg Depression Rating Scale (MADRS)-based primary ...
11/26/2024
202
BACKGROUND: Both esketamine nasal spray and transcranial magnetic stimulation (TMS) are indicated for treatment-resistant depression (TRD), but there are no guidelines on the sequence of...
11/26/2024
203
BACKGROUND: Esketamine nasal spray and second-generation antipsychotic augmentation (SGA) are approved therapies for treatment-resistant depression (TRD). Prospective randomized ESCAPE-TR...
11/26/2024
205
Hypothesis/Objective: To evaluate the impact of centanafadine (CTN)—a norepinephrine, dopamine, serotonin reuptake inhibitor—on patient-reported assessment of the frequency of core sympto...
11/26/2024
206
Background: We report secondary/exploratory endpoints assessing patient-reported depressive symptoms, insomnia symptoms, and health-related quality of life (HRQoL) from a phase 3, double-...
11/26/2024
207
Depression treatment remains a significant clinical challenge due to the variability in patient responses to antidepressant medications. Outside of pharmacogenetic testing, established mo...
11/26/2024
23
Abstract: Background: Lumateperone is FDA-approved to treat schizophrenia and bipolar depression. Adjunctive lumateperone 42mg efficacy and safety was demonstrated in patients with major ...
07/10/2025
#33
The SAVITRI study evaluated osavampator, a selective positive allosteric modulator of the AMPA receptor (AMPA-PAM), in adults with MDD. Compared with placebo, once-daily oral administrati...
10/17/2025
#92
This study developed and refined a conceptual model (CM) to assess psychosocial functioning in people living with schizophrenia (PLS), integrating insights from a targeted literature revi...
10/17/2025
#153
Individuals can experience moderate/severe multidimensional impact of TD even when individual AIMS component scores are mild in severity. Pronounced movements involving the muscles of fac...
10/17/2025
#168
Converging results from qualitative research (literature review, clinician interviews, and patient interviews) yielded a new conceptual disease model of PTSD that describes signs, symptom...
10/17/2025
#172
Cognitive processing therapy (CPT) can be effective in treating posttraumatic stress disorder (PTSD). Stellate ganglion block (SGB), which is an anesthetic injection that helps “reset” sy...
10/17/2025
#1
This study generated updated prevalence estimates for generalized anxiety disorder in adults in the US using real-world data, in addition to contextualizing findings through a systematic ...
10/17/2025
#3
This study assessed suicidal ideation among U.S. adults using 2022 NHWS data, with a focus on individuals with GAD and MDD. Overall, 28.4% U.S. adults reported recent suicidal thoughts, w...
10/17/2025
#17
This study surveyed psychiatrists from the US, Germany, and France on the treatment of MDD, BPD, and PTSD. Key findings include the importance of reducing suicidal ideation in MDD, varied...
10/17/2025
#20
This qualitative study explored functional impacts and outcome priorities through interviews with 15 adults with Major Depressive Disorder (MDD) and 5 clinicians. Patients reported widesp...
10/17/2025
#21
This post hoc analysis of a randomized double-blind study (NCT04599855) evaluated changes in the 5-item Montgomery-Åsberg Depression Rating Scale anhedonia factor score (a composite of it...
10/17/2025
#24
Using the PatientsLikeMe community, a 24-week real-world study was conducted in individuals with major depressive disorder (MDD) to assess goal-setting behaviors and clinical outcomes. Su...
10/17/2025
#26
Short Description: This Phase 3, double-blind, randomized study (NCT04959032) investigated the efficacy and safety of lumateperone 42 mg for relapse prevention in adult patients with schi...
10/17/2025
#41
Residual symptoms during antidepressant therapy (ADT), such as sleep disturbances and cognitive impairment, may signal incomplete ADT response and relapse risk. This study measured residu...
10/17/2025
#43
This study evaluated the cardiometabolic risks of pharmacologic treatments for MDD through a systematic review and network meta-analysis of randomized controlled trials. Results were rank...
10/17/2025
#64
A machine learning model to identify baseline factors predictive of response to aripiprazole once-monthly (AOM) in patients diagnosed with bipolar I disorder (BP-I) was developed using de...
10/17/2025
#72
Up to 50% of adults with schizophrenia switch antipsychotic medication within 2 years of treatment initiation. We conducted a real-world analysis of strategies used by healthcare provider...
10/17/2025
#79
This real-world claims analysis compared combined olanzapine/samidorphan (OLZ/SAM) versus olanzapine in patients with bipolar I disorder. OLZ/SAM was associated with significantly better ...
10/17/2025
#83
Short description: Prior pharmacokinetic studies of X/T in healthy volunteers showed dosing with food reduced trospium bioavailability, potentially impacting tolerability. This open-label...
10/17/2025
#96
TV-44749 is a once-monthly subcutaneous long-acting injectable olanzapine, designed to provide sustained efficacy without the risk of post-injection delirium/sedation syndrome (PDSS). Her...
10/17/2025
#119
CRESCENDO was a survey of the patient experience in adults with narcolepsy type 1. This subgroup analysis examined residual symptoms among respondents who reported satisfaction with curre...
10/17/2025
#124
Jazz DUET (NCT05875974) was a patient-centric, prospective, single-arm, open-label study evaluating effectiveness of low-sodium oxybate (LXB) in IH or narcolepsy. In participants with IH,...
10/17/2025
#167
Severe hypothyroidism can present with predominant psychiatric and cognitive symptoms, making diagnosis challenging when classic somatic signs are absent. This poster explores the neurops...
10/17/2025
#185
A 65-year-old male veteran with no prior psychiatric history and a past medical history of seizure disorder developed severe, treatment-resistant depression after witnessing his mother’s ...
10/17/2025
#187
This project explores the integration of mindfulness meditation with esketamine in the treatment of major depressive disorder. Conducted as a quasi-experimental pilot, the study involved ...
10/17/2025
1
Objectives: Generalized anxiety disorder (GAD) is associated with considerable health and economic burden, yet contemporary US epidemiologic estimates remain limited and inconsistent. Th...
04/20/2026
10
BackgroundOral antipsychotics (OAPs) are commonly used to manage schizophrenia but are often associated with nonadherence, leading to increased healthcare resource utilization (HCRU). Lo...
04/20/2026
100
Background: Individuals with schizophrenia often switch antipsychotics. A trial of xanomeline and trospium chloride (X/T) requiring washout of prior antipsychotics (pAPD) provided an opp...
04/20/2026
101
Abstract: Background: Antipsychotics (APs) can cause tardive dyskinesia (TD) and can have low adherence, leading to poor clinical outcomes. We analyzed real-world AP use, healthcare resou...
04/20/2026
102
Abstract: Background: For over 70 years, pharmacologic treatment of schizophrenia has relied on D2 dopamine receptor antagonists, largely confining treatment strategies to switching or co...
04/20/2026
103
Abstract: Olanzapine is an effective, commonly used, first-line treatment for schizophrenia. However, intramuscular (IM) long-acting injectable (LAI) olanzapine pamoate use in clinical pr...
04/20/2026
104
Abstract: Olanzapine is an effective treatment for schizophrenia but has metabolic adverse effects including weight gain. As ~30-86% of patients treated with olanzapine gain weight, early...
04/20/2026
105
Abstract: In schizophrenia treatment, adherence to oral antipsychotics is challenging and can lead to poor outcomes.
04/20/2026
106
Abstract: Introduction: Ulotaront is a trace amine-associated receptor 1 (TAAR1) agonist with no dopamine D2 receptor blockade in development for schizophrenia. Phase 2 studies demonstrat...
04/20/2026
107
Abstract: Introduction: Ulotaront is a trace amine-associated receptor 1 agonist (TAAR1) with 5-HT1A agonist activity under investigation for treatment of schizophrenia, major depressive ...
04/20/2026
108
Abstract: Functional impairment in schizophrenia results in substantial burden to patients, caregivers, and healthcare systems. Addressing this impairment remains a critical unmet need in...
04/20/2026
109
Abstract: Background: Prescription digital therapeutics (PDTs) are software-based interventions for managing and treating medical conditions prescribed by healthcare providers and dispens...
04/20/2026
11
Abstract: BackgroundNonadherence to oral antipsychotics (OAPs) among patients diagnosed with bipolar I disorder (BP-I) is associated with increased healthcare resource utilization (HCRU) ...
04/20/2026
110
Abstract: INTRODUCTION: This study compared real-world treatment patterns and healthcare resource utilization (HCRU) among early-in-illness patients with schizophrenia initiating the long...
04/20/2026
111
Abstract: Introduction: Narcolepsy, a chronic neurological disorder, presents with debilitating daytime sleepiness and other symptoms. We evaluated clinical and humanistic outcomes in ind...
04/20/2026
112
Abstract: Introduction: Idiopathic hypersomnia (IH) is a chronic neurological condition that manifests with excessive daytime sleepiness (EDS) and other debilitating symptoms. We used qua...
04/20/2026
113
Abstract: Background: Narcolepsy and idiopathic hypersomnia (IH) are associated with higher comorbidity burden and healthcare costs, compared with the general population. This study descr...
04/20/2026
114
Abstract: Introduction: Long-term safety and tolerability of once-nightly sodium oxybate (ON-SXB) were investigated in the open-label/switch study RESTORE (NCT04451668).
04/20/2026
115
Abstract: Introduction: People with narcolepsy (PWN) often experience diagnostic delays and difficulties with quality care, including healthcare provider (HCP) access and treatment-relate...
04/20/2026
116
Abstract: Introduction: Patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) often exhibit cognitive deficits. Solriamfetol (Sunosi®) is a dopami...
04/20/2026
117
Abstract: Background: We report double-blind (DB) and open-label extension (OLE) results from a Phase-3 study (NCT04533529) of adjunctive seltorexant, a first-in-class, selective, orexin-...
04/20/2026
118
Abstract: Introduction  AXS-12 (reboxetine) is a selective norepinephrine reuptake inhibitor and cortical dopamine modulator under investigation for narcolepsy. In the Phase 3 SYMPHONY st...
04/20/2026
119
Abstract: Introduction People with narcolepsy type 1 (NT1) often experience breakthrough symptoms, despite taking multiple medications. We report a subgroup analysis of respondents from ...
04/20/2026
12
Abstract: Background: Azetukalner is a novel, potent Kv7.2/7.3 potassium channel opener currently in Phase 3 development for epilepsy and major depressive disorder (MDD), with planned dev...
04/20/2026
120
Abstract: Introduction: This post-hoc analysis of DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment; NCT05875974) evaluated effectiveness/safety of low-so...
04/20/2026
121
Abstract: Introduction: Narcolepsy type 1 (NT1) is a chronic, rare neurological disorder characterized by excessive daytime sleepiness (EDS), cataplexy, disrupted nighttime sleep, hypnago...
04/20/2026
122
Abstract: Narcolepsy type 1 (NT1) is characterized by excessive daytime sleepiness and cataplexy, and associated with low cerebrospinal fluid orexin levels. The orexin receptor 2-selectiv...
04/20/2026
123
Abstract: Introduction: This post-hoc analysis of the DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) phase 4 trial (NCT05875974) evaluated effectivene...
04/20/2026
124
Abstract: Background: A previous report of patient interviews identified bothersome idiopathic hypersomnia (IH) impacts, including mood disturbances, cognitive dysfunction, and personal/p...
04/20/2026
125
Abstract: Introduction: Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment), a prospective, multicenter, multiple-cohort, single-arm, open-label study...
04/20/2026
126
Abstract: Objective: This analysis evaluated the effectiveness of low-sodium oxybate (LXB; Xywav®) on cognitive complaints, work productivity, and daily activities in participants with na...
04/20/2026
127
Abstract: Objective: Determine the efficacy of lemborexant (LEM) in patients with insomnia associated with depressive episodes.
04/20/2026
128
Abstract: Background:This analysis aimed to describe the impact of sleep inertia (SI) on cognition in people with idiopathic hypersomnia (IH).Methods:Commercially insured adults diagnosed...
04/20/2026
129
Abstract: Background: Excess sodium intake increases risk of hypertension/cardiovascular disease, which are common comorbidities in people with narcolepsy (PwN).
04/20/2026
13
Abstract: Background: Lumateperone is FDA-approved to treat schizophrenia and bipolar depression. Two Phase 3, randomized, double-blind, placebo-controlled studies (501, NCT04985942; 502,...
04/20/2026
130
Abstract: Introduction: Xanomeline-trospium chloride (X/T) received FDA approval for schizophrenia (SCZ) in September 2024. This is the first real-world study evaluating characteristics a...
04/20/2026
131
Abstract: Background: d-ATS is the only amphetamine-based transdermal treatment available for ADHD. Compared to oral drugs, transdermal formulations allow for greater individualized tailo...
04/20/2026
132
Abstract: Introduction: Adults with Attention Deficit Hyperactivity Disorder (ADHD) often struggle with inattentiveness and focus. While the efficacy of pharmacotherapy and cognitive beha...
04/20/2026
133
Abstract: BACKGROUND: ADHD is linked to high-risk driving and motor vehicle accidents, totaling $340 billion in costs in 2019. DYANAVEL XR (DXR) showed a 43% lower crash risk compared to ...
04/20/2026
134
Abstract: Lisdexamfetamine dimesylate (LDX) is a long-acting prodrug of dextroamphetamine approved for attention-deficit/hyperactivity disorder (ADHD) and for binge eating disorder in adu...
04/20/2026
135
Abstract: OBJECTIVE: We previously reported improvement in ADHD, depression and anxiety symptom rating scales in a "real-world," open-label decentralized trial of viloxazine ER (Qelbree®)...
04/20/2026
136
Abstract: Introduction: Viloxazine ER is an FDA-approved medication for pediatric and adult ADHD. Adult ADHD is often associated with psychiatric comorbidities. Here we present results of...
04/20/2026
137
Abstract: BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is a risk factor for motor vehicle accidents, including injuries and fatalities. The focus of this study was to asses...
04/20/2026
138
Abstract: Introduction: Well-documented risk factors associated with motor vehicle accidents (MVAs) include alcohol use, drug use, excessive speed, and cell phone use.1 A less publicized ...
04/20/2026
139
Abstract: Aim: To compare extended-release (ER) methylphenidate (MPH) and amphetamine (AMP) medications in terms of patient-reported side effects, including insomnia, appetite suppression...
04/20/2026
140
Abstract: Hypothesis/Objective: To evaluate the clinically meaningful treatment impact of centanafadine (CTN), a norepinephrine, dopamine, serotonin reuptake inhibitor, on inattention and...
04/20/2026
141
Abstract: Hypothesis/Objective: To compare efficacy measures and caregiver-completed exit survey data for children and adolescents treated for ADHD with centanafadine (CTN)-a norepinephri...
04/20/2026
142
Abstract: Hypothesis/Objective: This study evaluates the treatment impact of centanafadine (CTN), a norepinephrine, dopamine, serotonin reuptake inhibitor, on hyperactivity/impulsivity (H...
04/20/2026
143
Abstract: Hypothesis/Objective: The aim of this work was to evaluate the impact of centanafadine (CTN)-a norepinephrine, dopamine, serotonin reuptake inhibitor under investigation for ADH...
04/20/2026
144
Abstract: Hypothesis/Objective: To compare the executive functioning (EF) efficacy measure with patient exit interviews in children and adolescents treated for ADHD with centanafadine (CT...
04/20/2026
145
Abstract: Hypothesis/Objective: Attention-deficit/hyperactivity disorder (ADHD) is a chronic and prevalent neurodevelopmental disorder in adults, characterized by symptoms of inattention,...
04/20/2026
146
Abstract: Background: TV-46000 is a long-acting injectable (LAI) subcutaneous risperidone antipsychotic administered once monthly (q1m) or every 2 months (q2m) for schizophrenia. Transiti...
04/20/2026
147
Abstract: Background: Initiation requirements for long-acting injectable antipsychotics (LAIs) vary and may influence healthcare resource utilization and ease of use in patients hospitali...
04/20/2026
148
Abstract: Background: TV-46000 is a subcutaneous long-acting injectable antipsychotic (LAI) approved by the United States (US) Food and Drug Administration to treat adult patients with sc...
04/20/2026
149
Abstract: Long-acting injectable (LAI) antipsychotics with dosing intervals >1 month are becoming increasingly available for the treatment of schizophrenia. This study investigated pat...
04/20/2026
15
Abstract: Background: Lumateperone is FDA-approved to treat schizophrenia and depressive episodes associated with bipolar I or II disorder. This analysis of a positive, Phase 3, randomize...
04/20/2026
150
Abstract: Once-daily valbenazine is approved for tardive dyskinesia (TD) and chorea associated with Huntington's disease. In KINECT® 4 (K4: NCT02405091), early and sustained TD improvemen...
04/20/2026
151
Abstract: Background: Relapse prevention is a key treatment goal of schizophrenia. Previous analyses identified baseline characteristics associated with relapse with TV-46000 or placebo i...
04/20/2026
152
Abstract: Introduction: Once-daily valbenazine is approved for the treatment of tardive dyskinesia (TD). KINECT-PRO is the first clinical trial of an approved TD medication to assess and ...
04/20/2026
153
Abstract: Background: To examine the relationship between the multidimensional impact of tardive dyskinesia (TD) on daily functioning and the anatomical distribution and severity of TD-as...
04/20/2026
154
Abstract: Background: To identify patterns that may affect tardive dyskinesia (TD) diagnosis, the anatomical distribution of abnormal movements was compared in IMPACT-TD Registry particip...
04/20/2026
155
Abstract: Background: Data on treatment outcomes for tardive dyskinesia (TD) in long-term care (LTC) settings are limited. This study compared clinical outcomes of appropriate TD manageme...
04/20/2026
156
Abstract: Background: Deutetrabenazine is used for treatment of tardive dyskinesia (TD) and Huntington disease (HD)-related chorea. A survey study explored patient-reported experience wit...
04/20/2026
157
Abstract: Clozapine remains the gold standard for treatment-refractory schizophrenia due to its superior efficacy amongst other antipsychotics. However, it is associated with many adverse...
04/20/2026
158
Abstract: Introduction: Once-daily valbenazine is approved for the treatment of tardive dyskinesia (TD). KINECT-PRO is the first study of an approved TD medication to assess TD impacts, f...
04/20/2026
159
Abstract: Background: Cariprazine is a dopamine D3-preferring D3/D2 receptor and serotonin 5HT1A receptor partial agonist approved as an adjunctive treatment for adults with major depress...
04/20/2026
16
Abstract: Introduction: Rejoyn® (CT-152) is a US Food and Drug Administration-authorized prescription digital therapeutic adjunct to antidepressant medication for patients with major depr...
04/20/2026
160
Abstract: Introduction: The Tardive Dyskinesia Impact Scale (TDIS) is the only psychometrically validated patient-reported outcome (PRO) that measures the physical, social, and emotional ...
04/20/2026
161
Abstract: Agitation is a common problem associated with psychiatric disorders. Sublingual dexmedetomidine is FDA approved for the treatment of agitation associated with schizophrenia and ...
04/20/2026
162
Abstract: Introduction MM120 (lysergide; LSD D-tartrate) is under development by Mind Medicine, Inc. for generalized anxiety disorder (GAD) and major depressive disorder (MDD). A single-...
04/20/2026
164
Abstract: Introduction: A conceptual disease model (CDM) was developed using qualitative research methodology exploring the most relevant signs/symptoms and impacts from the perspective o...
04/20/2026
165
Abstract: Introduction: A conceptual disease model (CDM) was developed using qualitative research methodology to provide a comprehensive understanding of the patient experience with Parki...
04/20/2026
166
Abstract: Objective: Genome-wide association studies (GWAS) underpin modern psychiatric genetics and biomarker discovery, yet their accuracy hinges on rigorous control of population struc...
04/20/2026
167
Abstract: Severe hypothyroidism can disrupt neurocognitive and affective functioning through alterations in cerebral metabolism, neurotransmission, and immune signaling. While somatic fea...
04/20/2026
168
Abstract: Introduction: A conceptual disease model (CDM) was developed using qualitative research methodology in order to provide a comprehensive understanding of the patient experience w...
04/20/2026
169
Abstract: Symptoms of post-traumatic stress disorder (PTSD) can be characterized into four clusters. This post hoc analysis evaluated the efficacy of brexpiprazole in combination with ser...
04/20/2026
17
Abstract: Objective This study aimed to assess physician perspectives on the treatment of major depressive disorder (MDD), borderline personality disorder (BPD), and post-traumatic stress...
04/20/2026
170
Abstract: Post-traumatic stress disorder (PTSD) is a common trauma-based psychiatric disorder. People with PTSD experience a range of heterogenous and complex symptoms, which can vary ove...
04/20/2026
171
Abstract: Post-traumatic stress disorder (PTSD) is prevalent and associated with impaired functioning. This analysis evaluated patient-reported outcomes (PROs) for symptom severity and fu...
04/20/2026
172
Abstract: Introduction: Posttraumatic stress disorder (PTSD) is common among military personnel and veterans and is associated with numerous psychological problems and negative outcomes. ...
04/20/2026
174
Abstract: Benzodiazepines (BZDs) are known to carry a high risk for misuse and dependence, with alprazolam being commonly implicated for those with another comorbid substance use disorder...
04/20/2026
176
Abstract: Inhalant and volatile substance misuse present significant challenges to society, yet the treatment options have largely been overlooked. Currently, there are no FDA-approved ph...
04/20/2026
178
Abstract: Background: Postpartum depression (PPD) symptoms affect ~13.2% of US births. This study explores effectiveness of zuranolone, a once-daily 14-day oral treatment for PPD. This i...
04/20/2026
179
Abstract: Zuranolone (ZRN), a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors, was approved in the US (2023) as an oral, once-daily, 14-day treatment for adult...
04/20/2026
18
Abstract: Objective: Real-world insights may identify differences in major depressive disorder (MDD) disease progression and incremental burden among patients experiencing multiple episod...
04/20/2026
180
Abstract: Zuranolone (ZRN) is a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors and a neuroactive steroid approved in the US (2023) as an oral, once-daily, 14-...
04/20/2026
181
Abstract: Alzheimer's Disease is characterized by the degeneration of cholinergic neurons and reduced synaptic acetylcholine. Acetylcholinesterase inhibitors (AChEIs) offer a symptomatic ...
04/20/2026
182
Abstract: Objectives: This study aimed to compare the prevalence of depression, anxiety, and post-traumatic stress disorder (PTSD) in patients with Alzheimer's disease (AD) and non-Alzhei...
04/20/2026
183
Abstract: Objectives: This study aimed to examine the correlation between cognitive function, as assessed by the Montreal Cognitive Assessment (MoCA) score, and amyloid burden, represente...
04/20/2026
184
Abstract: Introduction: Alzheimer's disease (AD) agitation occurs in ~70% of individuals with AD. ACCORD-2 was a Phase-3, double-blind, placebo-controlled, randomized withdrawal study of ...
04/20/2026
185
Abstract: This case report highlights a 65-year-old male veteran with no psychiatric history who developed sudden-onset severe ruminative anxiety, intermittent depression, and panic attac...
04/20/2026
186
Abstract: Introduction: Valbenazine is a uniquely selective VMAT2 inhibitor approved for tardive dyskinesia (TD) and Huntington's disease chorea. Along with a higher risk for TD, elderly ...
04/20/2026
187
Abstract: Background:Esketamine is a novel antidepressant that has shown greater efficacy than traditional medications, and its efficacy may be enhanced with adjunctive psychotherapeutic ...
04/20/2026
188
Abstract: While most homelessness research emphasizes service expansion, there is limited attention to mental factors that cause unhoused persons to avoid or disengage from services. Exis...
04/20/2026
189
Abstract: Psilocybin is increasingly studied for psychiatric conditions, highlighted by recent positive phase 3 results for COMP360, a synthetic psilocybin formulation for treatment-resis...
04/20/2026
19
Abstract: Introduction: Rejoyn® (CT-152) is a US Food and Drug Administration-authorized prescription digital therapeutic adjunct to antidepressant medication for patients with major depr...
04/20/2026
191
Abstract: Clinical Language Profiling (CLP) is a practice-based framework for identifying executive function, emotional regulation, and symbolic fixation through client language in psycho...
04/20/2026
192
Abstract: Clinical trials have shown promising results for psilocybin in treating psychiatric conditions such as treatment-resistant depression and PTSD, with multiple biopharmaceutical c...
04/20/2026
193
Abstract: IntroductionDrug adherence and drug related problems (DRP) are common challenges in the treatment of serious mental illnesses (SMI). Home medication review (HMR) by pharmacists ...
04/20/2026
194
Abstract: According to the Health Resources and Services Administration, the supply of psychiatrists is projected to decline by 27% by 2030. To address this shortage, physician assistants...
04/20/2026
195
Abstract: The projected shortages of psychiatrists, combined with a rise in mental health (MH) disorders, are straining the US healthcare system. Physician assistants/associates (PAs) hav...
04/20/2026
196
Abstract: Podcasts are an increasingly popular educational resource for medical learners, including in psychiatry. While many are launched, few reach a wide audience, and limited research...
04/20/2026
197
Abstract: Background: CT-155/BI 3972080 is an investigational digital therapeutic for treatment of experiential negative symptoms (ENS) of schizophrenia.
04/20/2026
198
Abstract: BACKGROUND: Prescription Digital Therapeutics (PDTs) hold unique potential to improve mental health in underserved rural areas. However, community-specific differences in barrie...
04/20/2026
199
Abstract: Background: Negative symptoms of schizophrenia (NS) profoundly impact functional outcomes. As there are currently no approved pharmacotherapies for NS, innovative treatments are...
04/20/2026
2
Abstract: Background:Generalized anxiety disorder (GAD) is an impairing disorder encompassing several symptoms, including excessive worrying, restlessness, and irritability. This analysis...
04/20/2026
20
Abstract: Background: Major Depressive Disorder (MDD) impacts functional capacity beyond core mood symptoms. Treatment strategies often prioritize symptom reduction over functional recove...
04/20/2026
200
Bipolar disorder (BD) is a serious mental illness and a notoriously challenging disease for healthcare professionals to accurately diagnose and manage. As a result, high rates of undertre...
04/20/2026
201
While antipsychotic treatment is essential to achieving and maintaining remission in schizophrenia, conventional antipsychotic treatments are associated with numerous shortcomings, includ...
04/20/2026
202
Tardive dyskinesia (TD), which affects over 500,000 people in the United States (US), is an involuntary movement disorder associated with dopamine-receptor antagonists-most commonly antip...
04/20/2026
21
Abstract: Objective: This post hoc analysis of a phase 4, double-blind, multicenter study (NCT04599855) evaluated changes in anhedonia symptoms through 4 weeks of esketamine nasal spray (...
04/20/2026
22
Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and bipolar depression. Lumateperone adjunctive to antidepressant therapy (ADT) demonstrated sig...
04/20/2026
24
Abstract: Background: Major depressive disorder (MDD) remains a leading cause of disability, and many patients do not achieve remission. Goal-setting can direct desirable behavioral chang...
04/20/2026
25
Abstract: Background: Seltorexant, a first-in-class, selective, orexin-2 receptor antagonist, normalizes hyperarousal and promotes physiological sleep. Significant antidepressant effects ...
04/20/2026
26
Abstract: Background: Lumateperone is an FDA-approved antipsychotic for treating schizophrenia and bipolar depression. This Phase 3, multicenter, multinational, double-blind, placebo-cont...
04/20/2026
27
Abstract: Major depressive disorder (MDD) is a leading cause of disability, impacting 280 million people worldwide. The current pharmacological standard of care is selective serotonin and...
04/20/2026
28
Abstract: Introduction: Major depressive disorder (MDD) is a common and serious mood disorder marked by persistent low mood, loss of interest or pleasure, and symptoms, significantly impa...
04/20/2026
29
Abstract: Introduction: Cariprazine is a dopamine D3 preferring D3/D2 and serotonin 5-HT1A receptor partial agonist atypical antipsychotic approved by the US Food and Drug Administration ...
04/20/2026
3
Abstract: Background: Suicidal ideation (SI) is a growing public health issue, particularly among individuals with mental health conditions. This study examines the prevalence of SI among...
04/20/2026
30
Abstract: Background: There is limited evidence on comparative persistence among atypical antipsychotics (AAs) approved for bipolar I (BP-I) depression. This study compared real-world tre...
04/20/2026
31
Abstract: Introduction:Sleep disturbances occur in psychiatric diseases, and are associated with poor outcomes.However, sleep medication may increase drug-drug interactions, adverse event...
04/20/2026
32
Abstract: Background: There is limited evidence on comparative treatment persistence among atypical antipsychotics (AAs) used for bipolar I (BP-I) disorder. This study evaluated real-worl...
04/20/2026
33
Abstract: Osavampator (NBI-1065845/TAK-653), a selective positive allosteric modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPA-PAM), was evaluated ...
04/20/2026
34
Abstract: Major depressive disorder (MDD) remains a leading cause of disability worldwide. Approximately two-thirds of individuals with MDD do not remit in response to first-line therapie...
04/20/2026
35
Abstract: Introduction: Cariprazine is a dopamine D3 preferring D3/D2 and serotonin 5-HT1A receptor partial agonist atypical antipsychotic(AA) approved for bipolar I disorder (BP-I). Info...
04/20/2026
36
Abstract: Objective: To evaluate the efficacy and safety of esketamine nasal spray (ESK) monotherapy in adults with treatment-resistant depression (TRD) from a multicenter study (NCT04599...
04/20/2026
37
Abstract: Background: The "brightening effect" in major depressive disorder (MDD) refers to improvements in a subset of symptoms (eg, loss of interest and self-motivation) occurring in th...
04/20/2026
38
Abstract: Background: Major depressive disorder (MDD) is often treated with antidepressants such as SSRIs, bupropion, and vortioxetine, but their effectiveness for MDD symptoms varies ove...
04/20/2026
39
Abstract: Approximately 50% of patients with major depressive disorder (MDD) discontinue their antidepressant medication within 6 months, increasing risk of relapse. Pharmacogenomic test...
04/20/2026
4
Abstract: Background: Generalized anxiety disorder (GAD) is a prevalent and chronic mental health disorder that is associated with substantial psychiatric and physical comorbidity. This s...
04/20/2026
40
Abstract: Background: Real-world data on antidepressant treatment (ADT) patterns and residual symptoms in depression are limited. Comorbidities, including anxiety and substance use disord...
04/20/2026
41
Abstract: Background: Residual symptoms are ongoing depressive symptoms occurring during antidepressant treatment (ADT). Patients with residual symptoms have increased risk of relapse and...
04/20/2026
42
Abstract: Introduction AXS-12 (reboxetine) is a highly selective norepinephrine reuptake inhibitor and cortical dopamine modulator under development for narcolepsy. The ENCORE study evalu...
04/20/2026
43
Abstract: Objective: Pharmacologic treatments for major depressive disorder (MDD), including antidepressants and adjunctive antipsychotics, are associated with varying degrees of cardiome...
04/20/2026
44
Abstract: Objective: This post hoc analysis of SUSTAIN-3 (NCT02782104), an open-label long-term extension study of flexibly dosed esketamine nasal spray (ESK) plus ongoing oral antidepres...
04/20/2026
45
Abstract: Introduction:Esketamine nasal spray (ESK) is approved for treatment of adults with treatment-resistant depression as monotherapy or with an oral antidepressant (OAD). SUSTAIN-3 ...
04/20/2026
46
Abstract: Objective: This post hoc analysis of a phase 4, double-blind, multicenter study (NCT04599855) examined the effect of esketamine nasal spray (ESK) monotherapy on emotional blunti...
04/20/2026
47
Abstract: Background: In the treatment of MDD, critical needs remain for improved patient outcomes through medications with novel mechanisms of action (MOA). Auvelity® (dextromethorphan 4...
04/20/2026
48
Abstract: In patients with major depressive disorder (MDD), achieving remission often involves a lengthy trial-and-error process to identify effective medication. Pharmacogenomic (PGx) te...
04/20/2026
49
Abstract: Background: Major depressive disorder is a substantial disability with 10-30% of patients meeting criteria for TRD. VLS-01-BU (buccal film containing N,N-dimethyltryptamine (DMT...
04/20/2026
5
Abstract: Background: Generalized Anxiety Disorder (GAD) is among the most common psychiatric disorders; however effective and well-tolerated pharmacotherapies remain an unmet need. This ...
04/20/2026
50
Abstract: Introduction: While photobiomodulation (PBM) shows emerging potential for treating mood disorders, its safety and efficacy in patients with major depressive disorder (MDD) remai...
04/20/2026
51
Abstract: Treating depression resistant to conventional medical management has always been a dilemma. This has led to further exploration of the role of immunotherapy which is commonly us...
04/20/2026
52
Abstract: Background:Anhedonia is a core major depressive disorder(MDD) symptom.Cariprazine is an approved adjunctive therapy for MDD in adults. Short-term trials showed that cariprazine ...
04/20/2026
53
Abstract: Background:This phase 3, multicenter, open-label, long-term (26-week), flexible-dose (1.5-4.5 mg/day) study assessed long-term safety and tolerability of cariprazine used adjunc...
04/20/2026
54
Abstract: Introduction: CT-152 is a prescription digital therapeutic adjunct to antidepressant medication for patients with major depressive disorder (MDD) that has shown benefit over sha...
04/20/2026
55
Abstract: Introduction: CT-152 is a prescription digital therapeutic adjunct to antidepressant medication for patients with major depressive disorder (MDD). In the Mirai trial (NCT0477028...
04/20/2026
56
Abstract: Introduction: CT-152 is a prescription digital therapeutic adjunct to antidepressant medication for patients with major depressive disorder (MDD). This post hoc analysis of the ...
04/20/2026
57
Abstract: Background: Lumateperone is FDA-approved to treat schizophrenia and bipolar depression. In a randomized trial (Study 403; NCT04285515) lumateperone 42mg demonstrated efficacy an...
04/20/2026
58
Abstract: Introduction: Generalized anxiety disorder (GAD) and major depressive disorder (MDD) are leading causes of disease burden. >50% of patients with GAD also have MDD, and effect...
04/20/2026
59
Abstract: Introduction: Major depressive disorder (MDD) is common among US veterans. Esketamine is an intranasal spray approved for treatment-resistant depression (TRD).Objective: To desc...
04/20/2026
60
Abstract: Objective: Esketamine nasal spray and second-generation antipsychotic augmentation (SGA) are approved therapies for treatment-resistant depression (TRD). Prospective randomized ...
04/20/2026
61
Abstract: Objective: Both esketamine nasal spray and transcranial magnetic stimulation (TMS) are indicated for treatment-resistant depression (TRD), but there are no guidelines on the seq...
04/20/2026
62
Abstract: Background: Major depressive disorder (MDD) is associated with substantial disability burden. We compared real-world disability days, claims, and costs among patients with MDD i...
04/20/2026
63
Abstract: There is limited evidence on treatment persistence among atypical antipsychotics (AAs) used for bipolar I (BP-I) disorder and as adjunctive treatment for major depressive disord...
04/20/2026
64
Abstract: This abstract describes the development of a machine learning model to identify baseline factors predicting response to aripiprazole once-monthly (AOM) in patients diagnosed wit...
04/20/2026
65
Abstract: This abstract describes the development of a machine learning model to identify baseline factors predictive of response to aripiprazole once-monthly (AOM) in patients diagnosed ...
04/20/2026
66
Abstract: Introduction: Poor insight adversely affects prognosis in schizophrenia. These post hoc analyses assessed the efficacy of aripiprazole once-monthly (AOM) 400 mg (AOM 400) and ar...
04/20/2026
67
Abstract: Background: ARISE (NCT05145413) evaluated adjunctive xanomeline and trospium chloride (X/T) in adults with schizophrenia on stable background antipsychotic (bAPD) therapy. The p...
04/20/2026
68
Abstract: Background: Population pharmacokinetic (PopPK) modeling provided support for the dose rationale of xanomeline and trospium chloride (X/T) for the treatment of schizophrenia in a...
04/20/2026
69
Abstract: Diminished insight in schizophrenia is linked to lower treatment engagement and poorer outcomes. In addition, definitions of insight and terms used to describe the concept vary ...
04/20/2026
70
Abstract: Schizophrenia is commonly classified as a serious mental illness (SMI), emphasizing chronicity and disability. However, converging evidence from neuroscience, genetics, and epid...
04/20/2026
71
Abstract: Hyperthymic temperament is characterized by high energy, sociability, and resilience. It can be difficult to distinguish it from hypomania or bipolar spectrum disorders, particu...
04/20/2026
72
Abstract: Background: Approximately 30%-50% of adults with schizophrenia switch antipsychotic medication within 6-24 months of treatment initiation. This study aims to analyze retrospecti...
04/20/2026
73
Abstract: INTRODUCTION: This analysis examined lipid/glycemic parameters across patient subgroups in a 4-year, open-label study of combined olanzapine/samidorphan (OLZ/SAM) in adults with...
04/20/2026
74
Abstract: INTRODUCTION: Combined olanzapine and samidorphan (OLZ/SAM) received US FDA approval in 2021 for the treatment of adults with schizophrenia or bipolar I disorder (BD-I) and was ...
04/20/2026
75
Abstract: INTRODUCTION: This analysis examined subgroup data from a 4-year, open-label study of combined olanzapine/samidorphan (OLZ/SAM) in adults with schizophrenia, schizophreniform di...
04/20/2026
76
Abstract: Background: Xanomeline and trospium chloride (X/T, formerly KarXT) is approved for the treatment of adults with schizophrenia in the United States. The efficacy and safety of X/...
04/20/2026
77
Abstract: Background: Xanomeline/trospium chloride (X/T) is the first approved schizophrenia treatment with no direct D2 dopamine receptor binding activity. Given its unique and complemen...
04/20/2026
78
Abstract: Background: The dual M1/M4 muscarinic receptor agonist xanomeline combined with the pan-muscarinic receptor antagonist trospium chloride is approved by the U.S. Food and Drug Ad...
04/20/2026
79
Abstract: INTRODUCTION: Weight gain associated with antipsychotic treatment may contribute to nonadherence and subsequent increased risk of hospitalization. Combined olanzapine/samidorpha...
04/20/2026
8
Abstract: Rabies hysteria, though historically documented, remains an underrecognized psychiatric manifestation in modern medicine. This poster presents a striking case of a 63-year-old P...
04/20/2026
80
Abstract: INTRODUCTION: Weight gain associated with antipsychotic treatment may contribute to nonadherence and subsequent increased risk of hospitalization. Combined olanzapine/samidorpha...
04/20/2026
81
Abstract: INTRODUCTION: Combined olanzapine/samidorphan (OLZ/SAM) is approved for the treatment of schizophrenia and bipolar I disorder (BD-I). In real-world studies, OLZ/SAM treatment si...
04/20/2026
82
Abstract: Background: Xanomeline/trospium (X/T), which combines the dual M1/M4 muscarinic agonist xanomeline with the peripherally restricted pan-muscarinic receptor antagonist trospium c...
04/20/2026
83
Abstract: Background: In pharmacokinetic studies of xanomeline and trospium chloride (X/T), dosing with food reduced trospium bioavailability, potentially impacting tolerability. This stu...
04/20/2026
84
Abstract: This case series describes clinical characteristics and changes in mental, socioemotional, and physical domains of individuals with tardive dyskinesia (TD) after valbenazine tre...
04/20/2026
85
Abstract: Background: Xanomeline and trospium chloride (X/T) demonstrated significant improvement in PANSS total score compared with placebo in the pivotal EMERGENT-2 (NCT04659161) and EM...
04/20/2026
86
Abstract: Once-a-month paliperidone palmitate (PP1M) long-acting injectables are effective for schizophrenia and schizoaffective disorder. In practice, higher-than-recommended maintenance...
04/20/2026
87
Abstract: Background: Paliperidone palmitate (PP) 6-month (PP6M) is the longest-acting injectable antipsychotic approved for the treatment of adult schizophrenia patients adequately stabi...
04/20/2026
88
Abstract: Introduction: Long-acting injectable (LAI) antipsychotics with reduced dosing frequency may improve treatment outcomes in settings like Rwanda where standard-of-care for schizop...
04/20/2026
89
Abstract: Background: Persistent negative symptoms in schizophrenia are a major contributor to long-term functional impairment and disability. Paliperidone palmitate 6-month formulation (...
04/20/2026
9
Abstract: BackgroundNonadherence to oral antipsychotics (OAPs) in schizophrenia is common and contributes to increased healthcare resource utilization (HCRU) and costs. The long-acting in...
04/20/2026
90
Abstract: Background: Xanomeline and trospium chloride (X/T) is the first approved treatment for schizophrenia in adults that is a dual M1/M4 preferring muscarinic receptor agonist. Despi...
04/20/2026
91
Abstract: Rationale: This study assessed treatment patterns and adherence among patients with a diagnosis of schizophrenia receiving antipsychotic medications.
04/20/2026
92
Abstract: INTRODUCTION:Schizophrenia is a serious mental health disorder impacting all aspects of life in people living with schizophrenia (PLS), many of whom have a limited response to c...
04/20/2026
93
Abstract: Background: In addition to hallucinations and delusions, people with schizophrenia may exhibit hostility, which is associated with aggressive and violent behavior during acute e...
04/20/2026
94
Abstract: LY03010 (brand name ERZOFRI®) is a newly approved once-a-month paliperidone palmitate (PP1M) extended-release injectable suspension with a differentiated single initial injectio...
04/20/2026
95
Abstract: TV-44749 is an innovative, subcutaneous, long-acting injectable olanzapine for treatment of schizophrenia, designed to provide sustained efficacy and eliminate the risk of post-...
04/20/2026
96
Abstract: Long-acting injectable (LAI) antipsychotics improve adherence and outcomes in adults with schizophrenia. Olanzapine is available as an intramuscular LAI; however, post-injection...
04/20/2026
97
Abstract: TV-44749 is an innovative, subcutaneous long-acting injectable (LAI) olanzapine designed to provide sustained efficacy over the dosing interval without the post-injection deliri...
04/20/2026
98
Abstract: Tardive Dyskinesia Impact Scale (TDIS) evaluates TD symptom impact over the previous 7 days and was a KINECT®3, KINECT®4, and KINECT-PRO outcome. Objectives were to estimate min...
04/20/2026
99
Abstract: Background: Experiential negative symptoms (ENS) of schizophrenia include avolition, asociality, and anhedonia, which impact quality of life and functioning. This study assessed...
04/20/2026